Shenzhen Hepalink to acquire Scientific Protein Laboratories for US$337.5m

Published: 7-Jan-2014
Ingredients Finance

Combined company will be a global leader in Heparin Sodium API supply


Chinese firm Shenzhen Hepalink Pharmaceutical plans to buy US-based Scientific Protein Laboratories (SPL), a manufacturer and supplier of active pharmaceutical ingredients (APIs), for US$337.5m.

With the deal, the firm aims to expand its presence as a leading supplier of heparin worldwide, while providing greater product development and growth opportunities in new markets for its full line of APIs, including pancreatic enzyme and heparin products.

Li Li, Chairman and Chief Executive of Hepalink, said the deal would enable the firm to 'further enhance the stability and safety of the supply of the heparin product raw materials'.

Robert Mills, Chief Executive of SPL, added that the deal would 'expand our ability to develop and grow both our domestic and international businesses and to continue to conduct cutting-edge research on new products. We do not anticipate any changes in how we currently do business.'

The transaction is expected to be completed during the first half of 2014. After completion, SPL’s management will remain in place, as will its 204 employees in the US. SPL’s main facility is in Waunakee, Wisconsin.

  • Companies:
  • Scientific Protein Laboratories LLC
  • Shenzhen Hepalink Pharmaceutical Co. Ltd
See more

You may also like

Finance

Hepalink USA to acquire Cytovance Biologics

Read more
Hepalink investment will give Cytovance the opportunity to develop both its domestic and international businesses and to secure its plans to expand its Oklahoma City facilities

Trending Articles

  1. Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
  2. Vetter strengthens senior management team for growth Three new managing directors to support global sustainable development
  3. CDMO Adragos Pharma acquires aseptic fill-finish manufacturing expert, Baccinex Baccinex has significant knowledge in sterile fill-finish processes for both lyophilised and liquid vials
  4. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  5. Abzena Abzena is the leading end-to-end bioconjugate and complex biologics CDMO + CRO. From discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development of new treatments for patients in need. With the ability to tailor our strategy and customer experience to each project, Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their molecule. Our global locations include San Diego (CA, USA), Bristol (PA, USA), and Cambridge (UK).

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Finance

Hepalink USA to acquire Cytovance Biologics

Hepalink investment will give Cytovance the opportunity to develop both its domestic and international businesses and to secure its plans to expand its Oklahoma City facilities
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Manufacturing

CDMO Adragos Pharma acquires aseptic fill-finish manufacturing expert, Baccinex

Baccinex has significant knowledge in sterile fill-finish processes for both lyophilised and liquid vials
Research & Development

Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics

Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
Manufacturing

Vetter strengthens senior management team for growth

Three new managing directors to support global sustainable development
Finance

Merck attains $588m global license for PD-1/VEGF bispecific antibody from LaNova Medicines

The bispecific antibody is designed for oncological indications and functions by inhibiting the PD-1/PD-L1 and the VEGF/VEGFR receptor signalling pathways
Research & Development

Syncona launches early-stage drug development company, Slingshot Therapeutics

The novel early-stage pharmaceutical company aims to collaborate with academic institutions to bring their findings to the clinic, with their first programme centring around inflammatory disease
Subscribe now